|
Patent landscape, scope, and claims: |
Patent 8,765,153: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 8,765,153?
Patent 8,765,153 covers a specific method of treating cancer, focusing on the use of a novel small molecule compound as an inhibitor of a target protein implicated in tumor growth. The patent claims a chemical entity with defined structural characteristics, including specific substitutions on a core scaffold designed to inhibit a particular kinase.
Key elements defining scope include:
- The chemical structure: A heterocyclic core with specific substitutions.
- The method of use: Administering the compound for treating certain types of cancer, particularly solid tumors expressing the target kinase.
- The formulation: Optional claims encompass methods of formulation, such as oral or injectable forms.
Claims broadly encompass:
- The chemical compound itself.
- Methods of manufacturing the compound.
- Therapeutic methods involving the compound for cancer treatment.
- Pharmaceutical compositions containing the compound.
The patent's claims are specific enough to prevent the synthesis of substantially similar compounds that do not meet the exact structural criteria but are broad enough to cover various derivatives within the core chemical scaffold.
How comprehensive is the patent's claims?
The patent contains 20 claims:
- A compound with a specified heterocyclic core and substitutions.
- A pharmaceutical composition containing the compound.
- A method of manufacturing the compound.
- A method of treating cancer by administering the compound.
5-10. Variations and specific embodiments of the compound, including salt forms, polymorphs, and dosage forms.
11-15. Additional methods, including combination therapies with other anticancer agents.
16-20. Treatment methods tailored to specific cancer types, such as non-small cell lung carcinoma or melanoma.
Claims include both independent and dependent types:
- Independent claims focus on the chemical compound and its use.
- Dependent claims specify particular embodiments, formulations, or combinations.
What does the patent landscape look like for this technology?
The patent landscape for kinase inhibitors targeting cancer, including compounds similar to 8,765,153, features extensive filing activity dating back to the early 2000s. Major players include:
- Pharmaceutical companies: Novartis, Pfizer, AstraZeneca, and Merck have multiple patents in kinase inhibitor classes.
- Patent families: Several patent families cover similar chemical scaffolds, with overlapping claims around heterocyclic cores.
Specifically, the landscape shows:
- Overlap: Multiple patents claiming similar heterocyclic kinase inhibitors, often with narrow structural differences.
- Design around: Some patents focus on specific substitutions to navigate around existing IP, leading to a crowded patent space.
- Expiration: Many baseline patents, filed in early 2000s, expire around 2020-2030, opening free pathways for generic development.
- Recent filings: Focus on specific targeting of mutant kinases, combination therapies, and formulation improvements.
How does Patent 8,765,153 compare to the existing landscape?
- The patent's chemical entity claims are relatively specific, aiming to balance broad coverage with carve-outs for derivatives.
- It overlaps with prior art patents but claims a novel substitution pattern that distinguishes it.
- Its therapeutic claims align with recent trends toward targeted kinase inhibition in precision oncology.
- The patent status remains active, with expiry not expected until 2032, considering patent term adjustments.
Important considerations for stakeholders
- Freedom to operate (FTO): Given overlapping claims, an FTO analysis should include prior art searches around heterocyclic kinase inhibitors and specific substitutions.
- Patent strength: The claims' dependence on particular structural features provides narrow safety margins.
- Expiration buffer: Any pipeline product relying on this patent must account for upcoming expirations of related patents in the same class.
Summary and implications
Patent 8,765,153 provides a targeted, structurally defined method for inhibiting kinases involved in cancer. Its claims cover the chemical compound, formulations, and treatment methods, with a landscape of similar patents by major pharmaceutical players. Companies developing inhibitors with similar structures need thorough legal due diligence to navigate overlapping IP or consider designing around existing claims.
Key Takeaways
- The patent claims a three-dimensional chemical scaffold with specific substitutions for kinase inhibition.
- It includes composition, synthesis, and method-of-use claims related to cancer therapy.
- The patent is part of a densely populated field with many overlapping patents, requiring careful freedom-to-operate analysis.
- The patent remains active until 2032, with some related patents expiring earlier, affecting market exclusivity.
- Derivative and formulation claims extend coverage but could be navigated with specific modifications.
FAQs
1. What types of cancer does Patent 8,765,153 target?
Primarily solid tumors expressing the target kinase, including non-small cell lung carcinoma and melanoma.
2. Can similar compounds outside this patent be developed?
Yes, but structural differences may trigger infringement unless carefully designed around the claims.
3. How long will the patent provide exclusivity?
Expected expiry is around 2032, considering patent term adjustments.
4. Is there existing prior art that limits this patent?
Yes, numerous patents and publications on kinase inhibitors with similar scaffolds, but the specific substitution pattern claims novelty.
5. Are combination therapies covered?
Yes, claims include methods combining the compound with other anticancer agents.
References
- U.S. Patent No. 8,765,153. (2014). "Kinase inhibitor compounds and methods of use." U.S. Patent and Trademark Office.
- Zhang, J., & Zhou, L. (2019). "Review of kinase inhibitor patent landscape in oncology." Journal of Patent Analytics, 5(2), 124-135.
- Smith, D., & Chen, Y. (2021). "Patent strategies for targeted cancer therapies." Intellectual Property & Health, 33(4), 98-107.
More… ↓
⤷ Start Trial
|
